NCT07039578View on ClinicalTrials.gov

Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis

PHASE2RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

July 31, 2029

Conditions
Primary Light-Chain Amyloidosis
Interventions
BIOLOGICAL

CM336 Injection(Low dose group)

subcutaneous CM336 administration, step-up dosing, Dose and frequency of CM336 according to the protocol.

BIOLOGICAL

CM336 Injection(High dose group)

subcutaneous CM336 administration, step-up dosing, Dose and frequency of CM336 according to the protocol.

Trial Locations (2)

Unknown

RECRUITING

Peking Union Medical College Hospital, Beijing

RECRUITING

Institute of Hematology & Blood Diseases Hospital, Tianjin

Sponsors
All Listed Sponsors
lead

Keymed Biosciences Co.Ltd

INDUSTRY

NCT07039578 - Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis | Biotech Hunter | Biotech Hunter